NasdaqCM - Nasdaq Real Time Price USD

Elutia Inc. (ELUT)

1.9000

+0.0800

+(4.40%)

At close: May 13 at 4:00:02 PM EDT

Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

- New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m. PT - SILVER SPRING, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today reported strong first-quarter results for 2025 and highlighted key developments driving the adoption of EluPro™. In its first quarter post-launch, EluPro demonstrated strong momentum, establishing its position as a

GlobeNewswire 5 days ago

ELUT
+4.40%
Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio—including ProxiCor®, VasCure®, and Tyke®—following the conclusion of its distribution agreement with LeMaitre Vascular, Inc. The move allows Elutia to directly c

GlobeNewswire 12 days ago

ELUT
+4.40%
Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following info

GlobeNewswire 12 days ago

ELUT
+4.40%
Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29

SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer, will participate in Chardan’s Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025. Chardan's Data & Regulatory Catalysts – Navigating an Evolving Landscape – VirtualFormat: Fireside ChatDate and Time: Tuesday, April 29, 2025, 11:00 a.m. E

GlobeNewswire 21 days ago

ELUT
+4.40%
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

— Integration of clinical and patient-reported outcomes expected to further differentiate EluPro’s utility in cardiac implantable electronic device (CIED) procedures — SILVER SPRING, Md., April 21, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the initiation of an EluPro™ clinical study designed to collect patient outcome data in real-world clinical practice. EluPro, the first and only FDA-cleare

GlobeNewswire 22 days ago

ELUT
+4.40%
Elutia Confirms No Material Impact from Global Tariffs

SILVER SPRING, Md., April 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, today confirmed that the ongoing global tariff environment has had no material impact on its commercial or operational performance. Elutia sources, manufactures, and distributes 100% of its products within the United States, primarily from its Roswell, Georgia production facility and U.S.-based suppliers. These products include EluPro™, CanG

GlobeNewswire 29 days ago

ELUT
+4.40%
EluPro™ Named as 2025 Edison Award Winner

Innovative Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Pacemakers and Neurostimulators Earns Bronze in Post-Surgical Recovery Solutions Category SILVER SPRING, Md., April 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that EluPro™, the first ever FDA-cleared antibiotic-eluting bioenvelope was honored with a 2025 Bronze Edison Award™ for its innovative approach to reducing

GlobeNewswire last month

ELUT
+4.40%
Elutia to Participate in Upcoming Investor Conferences

SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences: LD Micro 15th Annual Invitational – New York, NYFormat: Presentation and 1x1 Meetings Presentation Date and Time: Thursday, April 10, 2025, 12:30 p.m. ET (9:30 a.m. PT)We

GlobeNewswire last month

ELUT
+4.40%
Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

Introduction of EluPro at Heart Rhythm 2025 in San Diego, April 25-27, 2025 SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, is proud to announce the debut of its EluPro™ Antibiotic-Eluting BioEnvelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators at the Heart Rhythm Society’s annual meeting (HRS 2025). Attendees will have the opportunity to experience fi

GlobeNewswire last month

ELUT
+4.40%
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

Seventh GPO Agreement Signed Since EluPro’s Launch SILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement with Advantus Health Partners (“Advantus”), to provide access of Elutia’s EluPro™ Antibiotic Eluting BioEnvelope to Advantus’ core group purchasing organizations (GPO) solutions portfolio. “Teaming up with Advantus is another major step forward

GlobeNewswire last month

ELUT
+4.40%
Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

— Rigorous testing demonstrates robust antimicrobial performance against bacterial strains relevant to cardiac implanted electronic device (CIED) infections — SILVER SPRING, Md., March 25, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of new preclinical data in the current issue of Antibiotics, further demonstrating the antimicrobial performance of its antibiotic-eluting biologic

GlobeNewswire last month

ELUT
+4.40%
Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

– Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization – SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the fourth quarter and full year ended December 31, 2024. Business Highlights: Strong Initial Market Uptake for EluPro: Since its pilot launch in the fourth quarter, Elu

GlobeNewswire 2 months ago

ELUT
+4.40%
Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company’s management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using

GlobeNewswire 2 months ago

ELUT
+4.40%
Private equity firms are Elutia Inc.'s (NASDAQ:ELUT) biggest owners and were hit after market cap dropped US$3.9m

Key Insights Elutia's significant private equity firms ownership suggests that the key decisions are influenced by...

Simply Wall St. 3 months ago

ELUT
+4.40%
Elutia Announces $15.0 Million Registered Direct Offering

SILVER SPRING, Md., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 5,520,000 shares of the Company’s Class A common stock at a purchase price of $2.50 per share and 480,000 prefunded warrants to purchase up to 480,000 shares of the Company’s Class A common stock at a purchase price of $2.499 per prefunded warrant in a registered direct offering. The pre

GlobeNewswire 3 months ago

ELUT
+4.40%
Elutia announces full U.S. commercial launch of EluPro

Elutia (ELUT) announced the U.S. commercial launch of EluPro, an FDA-cleared antibiotic-eluting biomatrix designed for use with cardiac implantable electronic devices and neurostimulators. This full launch follows a successful pilot program in which EluPro was introduced at select hospitals, demonstrating strong physician adoption and positive patient outcomes. During this initial phase, Elutia has submitted EluPro for approval with 136 hospital value analysis committees, initiated sales at 70 i

TipRanks 3 months ago

ELUT
+4.40%
Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand

First FDA-Cleared Antibiotic-Eluting BioEnvelope Now Available in U.S. for Implantable Pacemakers, Defibrillators, and Neurostimulators SILVER SPRING, Md., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT), a pioneer in drug-eluting biomatrix technologies, announced the U.S. commercial launch of EluPro™, the first and only FDA-cleared antibiotic-eluting biomatrix designed for use with cardiac implantable electronic devices (CIEDs) and neurostimulators. “EluPro is an exciting innovatio

GlobeNewswire 3 months ago

ELUT
+4.40%
Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners

SILVER SPRING, Md., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement with Vizient for the benefit of Southern Strategic Sourcing Partners (S3P), to provide access to Elutia’s innovative EluPro™ Antibiotic Eluting BioEnvelope to S3P’s extensive network of 993 acute care facilities, starting immediately. EluPro is the world’s first and only antibiotic-eluting biolo

GlobeNewswire 4 months ago

ELUT
+4.40%
Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.

SILVER SPRING, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced it has been awarded a national group purchasing agreement for Cardiac Rhythm Management Devices with Premier, Inc. Effective November 15, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the EluPro™ Antibiotic-Eluting BioEnvelope. “We ar

GlobeNewswire 5 months ago

ELUT
+4.40%
Elutia Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Elutia ( NASDAQ:ELUT ) Third Quarter 2024 Results Key Financial Results Revenue: US$5.92m (down 3.3% from 3Q 2023). Net...

Simply Wall St. 5 months ago

ELUT
+4.40%

Performance Overview

Return	ELUT	S&P 500 (^GSPC)
YTD	-49.20%	+0.08%
1-Year	-44.44%	+12.74%
3-Year	-69.38%	+46.29%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Elutia Inc. (ELUT)

Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales

Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio

Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29

Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice

Elutia Confirms No Material Impact from Global Tariffs

EluPro™ Named as 2025 Edison Award Winner

Elutia to Participate in Upcoming Investor Conferences

Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™

Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out

Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

Private equity firms are Elutia Inc.'s (NASDAQ:ELUT) biggest owners and were hit after market cap dropped US$3.9m

Elutia Announces $15.0 Million Registered Direct Offering

Elutia announces full U.S. commercial launch of EluPro

Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand

Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners

Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.

Elutia Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Performance Overview